Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
NCT01109004
Completed
The study is designed as a Phase III, multicenter trial of tandem autologous transplants plus maintenance therapy versus the strategy of single autologous transplant plus consolidation therapy with lenalidomide, bortezomib and dexamethasone (RVD) followed by maintenance therapy or single autologous transplant plus maintenance therapy as part of upfront treatment of multiple myeloma (MM). Lenalidomide will be used as maintenance therapy for three years in all arms.
Gender:
ALL
Ages:
70 years and below
Trial Updated:
12/08/2021
Locations: University of Michigan Medical Center, Ann Arbor, Michigan +1 locations
Conditions: Multiple Myeloma
Register for Updates
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT01412879
Completed
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy also work in different ways to kill more cancer cells or stop them from growing. It is not yet known whether rituximab is more effective with combination chemotherapy or bendamustine hydrochloride in treating patients wit... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/14/2021
Locations: Hickman Cancer Center at Bixby Medical Center, Adrian, Michigan +2 locations
Conditions: Lymphoma
Register for Updates
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
NCT02516423
Unknown
This randomized phase III trial compares ixazomib citrate, lenalidomide, dexamethasone and zoledronic acid with zoledronic acid alone to see how well they work when given after radiation therapy in treating patients with solitary plasmacytoma of bone. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells. Dexamethasone is a drug used in chemotherapy that may ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2021
Locations: Hickman Cancer Center, Adrian, Michigan +67 locations
Conditions: Solitary Osseous Plasmacytoma
Register for Updates
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
NCT03033511
Terminated
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2021
Locations: Henry Ford Health System /ID# 156712, Detroit, Michigan +1 locations
Conditions: Small Cell Lung Cancer
Register for Updates
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00103285
Completed
This randomized phase III trial is studying different combination chemotherapy regimens and comparing how well they work in treating patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.
Gender:
ALL
Ages:
Between 1 year and 9 years
Trial Updated:
06/11/2021
Locations: C S Mott Children's Hospital, Ann Arbor, Michigan +10 locations
Conditions: Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Register for Updates
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
NCT02612779
Completed
Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab (EN Cohort) to assess the safety and efficacy of these combination therapies for treatment of relapsed or refractory MM patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2021
Locations: University of Michigan, Ann Arbor, Michigan +1 locations
Conditions: Multiple Myeloma
Register for Updates
Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
NCT00671034
Completed
This randomized clinical trial is studying giving calaspargase pegol together with combination chemotherapy to see how well it works compared with giving pegaspargase together with combination chemotherapy in treating younger patients with newly diagnosed high-risk acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) ma... Read More
Gender:
ALL
Ages:
Between 2 years and 30 years
Trial Updated:
04/02/2021
Locations: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan
Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Register for Updates
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
NCT00075725
Completed
This randomized phase III trial is studying dexamethasone to see how well it works compared to prednisone during induction therapy. This trial is also studying methotrexate and leucovorin calcium to see how well they work compared to methotrexate alone during maintenance therapy in treating patients with newly diagnosed acute lymphoblastic leukemia (ALL). Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and leucovorin calcium, work in different ways to stop cancer cel... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
04/02/2021
Locations: C S Mott Children's Hospital, Ann Arbor, Michigan +10 locations
Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Register for Updates
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
NCT02431208
Completed
This multicenter, open-label, Phase I study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone or in combination with daratumumab and/or various immunomodulatory agents in participants with MM who have relapsed or who have undergone autologous stem cell transplantation (ASCT). Cycle length will be 21 days in Cohorts A to C and 28 days in Cohorts D to F.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2021
Locations: Univ of Michigan Medical Ctr, Ann Arbor, Michigan +2 locations
Conditions: Multiple Myeloma
Register for Updates
Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients
NCT01897714
Terminated
The study will explore escalating doses of melflufen in combination with dexamethasone in small groups of patients to find the maximum tolerated dose of melflufen. That dose will then be used to determine the efficacy and safety profile of melflufen in combination with dexamethasone in a larger group of patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2020
Locations: Karmanos Cancer Center, Detroit, Michigan
Conditions: Relapsed and/or Relapsed-refractory Multiple Myeloma
Register for Updates
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
NCT00821249
Completed
This is a 2-phase study during which patients with relapsed or refractory multiple myeloma (MM) or plasma cell leukemia (PCL), who have already received at least two previous treatments, will receive investigational study drug ARRY-520. The study has 3 parts. In the first part of the study, Phase 1, patients will receive increasing doses of study drug, with or without granulocyte-colony stimulating factor (G-CSF) support, in order to achieve the highest dose possible that will not cause unaccep... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2020
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Multiple Myeloma, Plasma Cell Leukemia
Register for Updates
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
NCT01248923
Completed
This is a Phase 1 study during which patients with relapsed or refractory multiple myeloma (MM) or plasma cell leukemia (PCL) will receive investigational study drug ARRY-520 and bortezomib, with or without dexamethasone, with granulocyte-colony stimulating factor (G-CSF) support. This study has 2 parts. In the first part, patients will receive increasing doses of study drug (2 dosing schedules will be evaluated) in combination with (1) bortezomib with G-CSF support or (2) bortezomib and dexame... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/28/2020
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan +1 locations
Conditions: Multiple Myeloma, Plasma Cell Leukemia
Register for Updates